Use of molecular imaging to quantify response to IKK-2 inhibitor treatment in murine arthritis

Arthritis and Rheumatism

Volumn 56, Issue 1, 2007, Pages 117-128

  Izmailova, Elena S ^a,d   Paz, Nancy ^a   Alencar, Herlen ^e   Chun, Miyoung ^b   Schopf, Lisa ^c   Hepperle, Michael ^c   Lane, Joan H ^d   Harriman, Geraldine ^d   Xu, Yajun ^d   Ocain, Timothy ^d   Weissleder, Ralph ^e   Mahmood, Umar ^e   Healy, Aileen M ^d   Jaffee, Bruce ^d  

^a MERRIMACK PHARMACEUTICALS   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Phenomix Corporation   (United States)

^d MILLENNIUM PHARMACEUTICALS INC   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN ANTIBODY; COLLAGEN TYPE 2; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ML 120B; RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; IMAGE ANALYSIS; JOINT; MOLECULAR IMAGING; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CARBOLINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION; I-KAPPA B KINASE; JOINTS; MICE; MICE, INBRED BALB C; NF-KAPPA B; NIACINAMIDE; RNA, MESSENGER; SPECTROMETRY, FLUORESCENCE; SPECTROSCOPY, NEAR-INFRARED; UP-REGULATION;

EID: 33846200742     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22303     Document Type: Article

References (27)

1. Ghosh S, Karin M. Missing pieces in the NF-κB puzzle. Cell 2002;109 Suppl:S81-96.
2. Tak PP, Firestein GS. NF-κ: a key role in inflammatory diseases. J Clin Invest 2001;107:7-11.
3. Van den Berg WB, van Kiel PL. Uncoupling of inflammation and destruction in rheumatoid arthritis: myth or reality? [editorial]. Arthritis Rheum 2005;52:995-9.
4. Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D, et al, for the ATTRACT Study Group. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy study. Arthritis Rheum 2005;52:1020-30.
5. Pahl HL. Activators and target genes of Rel/NF-κB transcription factors. Oncogene 1999;18:6853-66.
6. Bresnihan B. Pathogenesis of joint damage in rheumatoid arthritis. J Rheumatol 1999;26:717-9.
7. Tak PP, Bresnihan B. The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis [review]. Arthritis Rheum 2000;43:2619-33.
8. Trabandt A, Gay RE, Fassbender HG, Gay S. Cathepsin B in synovial cells at the site of joint destruction in rheumatoid arthritis. Arthritis Rheum 1991;34:1444-51.
9. Murphy G, Knauper V, Atkinson S, Butler G, English W, Button M, et al. Matrix metalloproteinases in arthritic disease. Arthritis Res 2002;4 Suppl 3:539-49.
10. Mengshol JA, Mix KS, Brinckerhoff CE. Matrix metalloproteinases as therapeutic targets in arthritic diseases: bull's-eye or missing the mark? [review]. Arthritis Rheum 2002;46:13-20.
11. Hansen T, Petrow PK, Gaumann A, Keyszer GM, Eysel P, Eckardt A, et al. Cathepsin B and its endogenous inhibitor cystatin C in rheumatoid arthritis synovjum. J Rheumatol 2000;27:859-65.
12. Han Z, Boyle DL, Manning AM, Firestein GS. AP-1 and NF-κB regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity 1998;28:197-208.
13. Rudin M, Weissleder R. Molecular imaging in drug discovery and development. Nat Rev Drug Discov 2003;2:123-31.
14. Nagashima K, Sasseville VG, Wen D, Bielecki A, Yang H, Simpson C, et al. Rapid TNFR1 dependent lymphocyte depletion in vivo with a selective chemical inhibitor of IKKβ. Blood 2006; 107:4266-73.
15. Carlsen H, Moskaug JO, Fromm SH, Blomhoff R. In vivo imaging of NF-κB activity. J Immunol 2002;168:1441-6.
16. Wunder A, Tung CH, Muller-Ladner U, Weissleder R, Mahmood U. In vivo imaging of protease activity in arthritis: a novel approach for monitoring treatment response. Arthritis Rheum 2004;50:2459-65.
17. Benito MJ, Murphy E, Murphy EP, van den Berg WB, FitzGerald O, Bresnihan B. Increased synovial tissue NF-κB1 expression at sites adjacent to the cartilage-pannus junction in rheumatoid arthritis. Arthritis Rheum 2004;50:1781-87.
18. Schopf L, Savinainen S, Anderson K, Kujawa J, DuPont M, Silva M, et al. IKKβ inhibition protects against bone and cartilage destruction in a rat model of rheumatoid arthritis. Arthritis Rheum 2006;54:3163-73.
19. Podolin PL, Callahan JF, Bolognese BJ, Li YH, Carlson K, Davis TG, et al. Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IκB kinase 2, TPCA-1 (2-[(aminocarbonyi)amino] -5-(4-fluorophenyl)-3-thiophene-carboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell proliferation. J Pharmacol Exp Ther 2005;312:373-81.
20. Ghosh S, May MJ, Kopp EB. NF-κ B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998;16:225-60.
21. Baldwin AS Jr. The NF-κ B and I κ B proteins: new discoveries and insights. Annu Rev Immunol 1996;14:649-83.
22. McIntyre KW, Shuster DJ, Gillooly KM, Warrier RR, Connaughton SE, Hall LB, et al. Reduced incidence and severity of collagen-induced arthritis in interleukin-12-deficient mice. Eur J Immunol 1996;26:2933-8.
23. Li Q, Bever CT Jr. Effect of protein kinase modulators on the regulation of cathepsin B activity in THP-1 human monocytic leukemia cells. Oncol Rep 1998;5:227-33.
24. Liuzzo JP, Petanceska SS, Moscatelli D, Devi LA. Inflammatory mediators regulate cathepsin S in macrophages and microglia: a role in attenuating heparan sulfate interactions. Mol Med 1999;5:320-33.
25. Maciewicz RA, Wotton SF. Degradation of cartilage matrix components by the cysteine proteinases, cathepsins B and L. Biomed Biochim Acta 1991;50:561-4.
26. Cunnane G, FitzGerald O, Hummel KM, Youssef PP, Gay RE, Gay S, et al. Synovial tissue protease gene expression and joint erosions in early rheumatoid arthritis. Arthritis Rheum 2001;44:1744-53.
27. Eeckhout Y, Vaes G. Further studies on the activation of procollagenase, the latent precursor of bone collagenase: effects of lysosomal cathepsin B, plasmin and kallikrein, and spontaneous activation. Biochem J 1977;166:21-31.